ONCO logo

ONCO Onconetix, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$3.15
+0.15 (+5.00%)

Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its develop…

Market Cap: $1.13Mwww.onconetix.com

Price

No data yet.

Social Signal Score

39
5d
—
30d
40
2 mentions
—
60d
41
5 mentions
—
90d
36
9 mentions
—
news: 9

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 1Hold 1Sell 0Strong Sell 0

Revenue

$102.9K
$0.00$237.3K$474.7K$712.0K
Mar 2021Sep 2026

Analyst Estimates

FY2025
$-1683000.00
$-1683000.00–$-1683000.00
1 analysts
FY2026
$-2006000.00
$-2006000.00–$-2006000.00
1 analysts
FY2027
$-2142000.00
$-2142000.00–$-2142000.00
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David Allan White
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
2.61
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-21.97
www.onconetix.com